• No results found

First in man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi functional T cell responses in ovarian, breast and prostate cancer patients

N/A
N/A
Protected

Academic year: 2020

Share "First in man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi functional T cell responses in ovarian, breast and prostate cancer patients"

Copied!
12
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Age, disease status, stage, response to last therapy and clinical outcome for subjects receiving a complete setof three injections
Table 2 Safety and reported adverse events, occurring in two or more subjects, which were possibly, probably ordefinitely related to DPX-0907 treatment
Figure 1 The generation of antigen-specific CD8+ T cells in DPX-0907 vaccinated ovarian, prostate and breast cancer patients
Table 5 The generation of multi-functional T cells in patients who responded to vaccination with DPX-0907

References

Related documents

radix-4 architectures, a large silicon area. overhead is their unwanted byproduct

Considering only women who received abortion care from public facility where there is shortage contraception supplies in study conducted in two of the region and failing to

incidence and distribution of advanced colorectal adenomas in patients undergoing colonoscopy for screening, surveillance, and symptoms.. haifeng

Query running time and number of queue pop- operations for Bidirectional Dijkstra’s algorithm on the graph for the general PRP problem. ―random‖, ―input‖

The extracted features are reduced using Principal Component Analysis (PCA) and tested with different types of machine learning algorithms for classification.. Classifications

In the quest for a new research agenda for process technology, we apply the vision of software de- velopment, Michael Jackson set out in his ICSE-17 keynote talk [Jackson, 1995] on

Keywords: graphene oxide, silver nanoparticles, graphene oxide-silver nanocomposite, antibacterial agent, MRSA, Escherichia